Animal Health Professionals Site

21 May 2015

New youngstock health initiative aims to cut alarming calf losses

MILTON KEYNES, UK, May 21 2015 – Beef Expo saw the launch of a major new industry-wide initiative aimed at improving the health of the nation’s youngstock.

The ‘Keeping Britain’s Youngstock Healthy’ campaign – orchestrated and driven by MSD Animal Health (a division of Merck & Co., Inc., Kenilworth, NJ, USA.)  – will help farmers, vets, the animal health trade and other industry stakeholders cut the alarming youngstock losses suffered by the British cattle sector.

“Nearly 2.5 million calves are born in Great Britain every year, but far too many fail to reach adulthood because of disease problems,” said Alfredo Sanz Moreno MRCVS from MSD Animal Health.

“On average 8% of calves are born dead or die within 24 hours of birth on British farms. These are appalling losses and significant costs the industry can ill afford to bear. Fortunately, industry stakeholders are committed to reversing the trend, but everyone must work together to give committed youngstock rearers the tools to make a real difference on farm. This new initiative aims to do just that,” he said.

This summer MSD Animal Health will roll out a multi-faceted, dynamic educational programme, which includes training and diagnostic tools for vets to help more proactive engagement with farmers over youngstock health issues, as well as best practice advice for calf rearers.

The initiative is supported by an educational website [] complete with practical video content and an opportunity to register for regular e-newsletters packed with topical youngstock management advice.

In commenting on the priority areas for improvement, Mr Sanz Moreno highlighted colostrum feeding practices, environmental management issues and disease prevention particularly.

“Unfortunately, up to 50% of calves born in Britain do not receive enough good quality colostrum. Addressing this alone would help the industry make great strides towards reversing such depressing youngstock loss statistics. It is also estimated that around 50% of livestock housing in Britain is not able to provide adequate ventilation. Infectious diseases too, particularly scours and pneumonia, continue to take their toll despite the fact that we have highly effective vaccines and other animal health products available to help farmers manage these problems,” he said.

About MSD Animal Health

Today's MSD is a global healthcare leader working to help the world be well. MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, NJ, USA., is the global animal health business unit of MSD. Through its commitment to the Science of Healthier Animals™, MSD Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit or connect with us on LinkedIn.

MSD forward-Looking Statement

This presentation includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of MSD’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; MSD’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of MSD’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

MSD undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in MSD’s 2014 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (